IL-1RL1/ST2 hFc Chimera, Human
IL-1RL1/ST2 HFc Chimera, Human

Immobilized Human IL-33, No Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for IL-1RL1/ST2 hFc Chimera, Human, hFc Tag with the EC50 of 9.8ng/ml determined by ELISA.

IL-1RL1/ST2 HFc Chimera, Human

Immobilized IL-1RL1/ST2 hFc Chimera, Human, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-IL-1RL1 Antibody, hFc Tag with the EC50 of 12.6ng/ml determined by ELISA.

IL-1RL1/ST2 HFc Chimera, Human

The purity of IL-1RL1/ST2 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

IL-1RL1/ST2 HFc Chimera, Human

IL-1RL1/ST2 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

IL-1RL1/ST2 hFc Chimera, Human

IL1RL1(also known as ST2) is a member of the IL1 receptor family and serves as the receptor for IL-33. The ST2 protein has two isoforms including sST2 and the membrane-bound ST2 receptor, referred to as ST2L. Preclinical studies have demonstrated that binding of IL-33 to ST2L elicits a cardioprotective effect. ST2/IL-33 signaling may play an important role in intestinal disease.
Z05467
¥31,712.00

Ask us a question
Product Introduction
Species Human
Protein Construction
IL-1RL1/ST2 (Lys19-Phe328)
Accession # Q01638-2		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 61.75 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 75-100 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • IL-1RL1/ST2 HFc Chimera, Human
    • IL-1RL1/ST2 HFc Chimera, Human

    Immobilized Human IL-33, No Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for IL-1RL1/ST2 hFc Chimera, Human, hFc Tag with the EC50 of 9.8ng/ml determined by ELISA.

  • IL-1RL1/ST2 HFc Chimera, Human
    • IL-1RL1/ST2 HFc Chimera, Human

    Immobilized IL-1RL1/ST2 hFc Chimera, Human, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-IL-1RL1 Antibody, hFc Tag with the EC50 of 12.6ng/ml determined by ELISA.

  • IL-1RL1/ST2 HFc Chimera, Human
    • IL-1RL1/ST2 HFc Chimera, Human

    The purity of IL-1RL1/ST2 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • IL-1RL1/ST2 HFc Chimera, Human
    • IL-1RL1/ST2 HFc Chimera, Human

    IL-1RL1/ST2 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background IL1RL1(also known as ST2) is a member of the IL1 receptor family and serves as the receptor for IL-33. The ST2 protein has two isoforms including sST2 and the membrane-bound ST2 receptor, referred to as ST2L. Preclinical studies have demonstrated that binding of IL-33 to ST2L elicits a cardioprotective effect. ST2/IL-33 signaling may play an important role in intestinal disease.
Synonyms IL1RL1; DER4; ST2; T1; FIT-1; IL33R; ST2L; ST2V; IL-1 R4; IL1R4; Ly84; MGC32623

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.